Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. (2020)

First Author: Poon E
Attributed to:  Institute of Cancer Research Confidence in Concept (ICR CiC) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1172/jci134132

PubMed Identifier: 33016930

Publication URI: http://europepmc.org/abstract/MED/33016930

Type: Journal Article/Review

Volume: 130

Parent Publication: The Journal of clinical investigation

Issue: 11

ISSN: 0021-9738